D.Western Therapeutics Institute 4576.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4576.T. It has been listed since 23 October 2009. In the fiscal year to 31 December 2025, it reported revenue of ¥387.6m and a net loss of ¥632.1m. At that date it held total assets of ¥2.17bn and shareholders' equity of ¥1.44bn.

D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. The company is headquartered in Nagoya, Aichi-Ken. The company went IPO on 2009-10-23. The firm generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The firm is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yuichi HidakaPresident, Chief Executive Officer, Representative Director, since 2006
• Ms. Sayako MatsubaraDirector
• Mr. Tetsuji AokiIndependent Director
• Mr. Eisaku NakamuraIndependent Director
• Mr. Yoshiyuki YamakawaIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.